Ocumetics Announces Significant Debt Conversion Strengthening Balance Sheet Ahead of Patient Study Milestones

(TheNewswire)

KeyHighlights

• $1.4 million of debenture principalconverted to common shares of Ocumetics 

• Debt conversion represents 35%reduction in outstanding debenture principal 

Calgary, Canada – TheNewswire -June 2, 2026 - Ocumetics Technology Corp.(“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QBO), a developer of advanced vision restoration technologies,is pleased to announce that debentureholders have converted $1.4million of their principal into common shares of the Company at aprice of $0.32 per share, resulting in the issuance of 4,375,000common shares, in aggregate.  The conversion represents 35% of theCompany’s previously outstanding debenture principal of $4million.

“These debenture conversions reflect the confidenceour investors and debenture holders continue to show in Ocumetics andour long-term vision,” said Dean Burns, President and CEO ofOcumetics. “We are actively managing our investments and stakeholderrelationships as we continue to advance our patient study and focus onachieving the next major milestones for the Company.”

In aggregate, the conversions represent $1.4 million indebenture principal being converted into common shares of the Company,significantly strengthening the Company’s balance sheet as Ocumeticsadvances toward key milestones in its ongoing patient study program.

The conversion of debt into equity is expected toimprove the Company’s financial flexibility and reduce ongoinginterest costs while aligning investor interests with the continuedadvancement of Ocumetics’ technology platform and clinicaldevelopment objectives.

The Company continues to advance toward key regulatorymilestones, including preparation for its planned InvestigationalDevice Exemption (“IDE”) submission to the U.S. Food and DrugAdministration.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QBO) is a Canadian research and product development companythat is dedicated to developing advanced vision correction solutionsthat enhance the quality of life for patients.  Through innovativeresearch and development, Ocumetics aims to transform the field ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing technologies.

Ocumetics is in the first-in-human early feasibilitystudy phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed a dynamic intraocular lens that fits withinthe natural lens compartment of the eye, potentially to eliminate theneed for corrective lenses.  It is designed to allow the eye’snatural muscle activity to shift focus from distance to near,providing clear vision at all distances without the help of glasses orcontact lenses, and without perceptible time lag.  

FOR FURTHER INFORMATION, PLEASECONTACT:

David Burwell

Director, Investor Relations        

dave.burwell@ocumetics.com

(403) 410-7907

Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theCorporation’s planned clinical trial program and other research anddevelopment activities and that they will be conducted as expected. Forward-looking statements are necessarily based upon a number ofestimates and assumptions that, while considered reasonable, aresubject to known and unknown risks, uncertainties, and other factorswhich may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances.  There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements.  The Corporationdisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, except as required by law.

Copyright (c) 2026 TheNewswire - All rights reserved.